Experts Advocate Broader Use of GLP-1 Drugs in Heart Disease Treatment

Experts Advocate Broader Adoption of GLP-1 Medications in Heart Disease Management At the conclusion of the ASPC 2025 Congress on Cardiovascular Disease Prevention, specialists emphasized the expanding role of glucagon-like peptide-1 (GLP-1) inhibitors in cardiovascular care. These medications have demonstrated substantial reductions in heart-related events and mortality rates, with additional benefits in weight loss and alleviating symptoms of heart failure. Medical professionals are encouraged to integrate GLP-1 therapies into their treatment protocols, as current cardiology guidelines support their use given their proven effectiveness. Recent clinical trials, such as SOUL and SURPASS, underscore the growing significance of GLP-1 agents, extending their application beyond traditional diabetes and obesity management to broader cardiovascular protection.